Silver Oak Securities Incorporated Makes New $244,000 Investment in Silk Road Medical, Inc (NASDAQ:SILK)

Silver Oak Securities Incorporated bought a new position in Silk Road Medical, Inc (NASDAQ:SILK) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 19,877 shares of the company’s stock, valued at approximately $244,000.

Other hedge funds also recently made changes to their positions in the company. CWM LLC grew its position in shares of Silk Road Medical by 151.5% in the 4th quarter. CWM LLC now owns 2,563 shares of the company’s stock worth $31,000 after acquiring an additional 1,544 shares in the last quarter. RiverPark Advisors LLC acquired a new position in shares of Silk Road Medical in the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC boosted its position in Silk Road Medical by 879.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,210 shares of the company’s stock valued at $52,000 after purchasing an additional 3,780 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Silk Road Medical by 28.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,295 shares of the company’s stock worth $139,000 after buying an additional 2,049 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Silk Road Medical during the 3rd quarter worth $144,000.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Argus upgraded Silk Road Medical from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Thursday, March 7th. JPMorgan Chase & Co. upped their price objective on Silk Road Medical from $19.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday. Stifel Nicolaus upped their price objective on Silk Road Medical from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Lake Street Capital started coverage on Silk Road Medical in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $20.00 price target for the company. Finally, Piper Sandler increased their price target on Silk Road Medical from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Silk Road Medical presently has a consensus rating of “Hold” and a consensus price target of $22.55.

Silk Road Medical Stock Performance

Shares of Silk Road Medical stock opened at $20.16 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 6.97 and a current ratio of 7.95. The business has a fifty day simple moving average of $17.63 and a 200-day simple moving average of $13.49. Silk Road Medical, Inc has a fifty-two week low of $6.08 and a fifty-two week high of $44.11.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.04. The business had revenue of $48.50 million during the quarter, compared to analyst estimates of $44.67 million. Silk Road Medical had a negative return on equity of 35.12% and a negative net margin of 29.02%. The company’s revenue was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.43) earnings per share. Research analysts predict that Silk Road Medical, Inc will post -1.39 earnings per share for the current year.

Insider Activity

In other news, insider Andrew S. Davis sold 5,481 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total transaction of $94,108.77. Following the completion of the sale, the insider now directly owns 287,773 shares of the company’s stock, valued at $4,941,062.41. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Andrew S. Davis sold 5,481 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $17.17, for a total transaction of $94,108.77. Following the completion of the sale, the insider now directly owns 287,773 shares of the company’s stock, valued at $4,941,062.41. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Marie L. Jones sold 2,602 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $17.17, for a total value of $44,676.34. Following the sale, the chief accounting officer now directly owns 76,894 shares of the company’s stock, valued at $1,320,269.98. The disclosure for this sale can be found here. Insiders sold a total of 20,457 shares of company stock valued at $351,247 over the last three months. Insiders own 6.70% of the company’s stock.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.